Abstract 602P
Background
Neoadjuvant radiation and oxaliplatin-based systemic therapy (Total Neoadjuvant Therapy – TNT) has been shown to increase response and organ-preservation rates in localized rectal cancer. However, trials have been heterogeneous regarding treatment protocols and few have used a watch-and-wait (WW) approach for complete responders. This trial evaluates if conventional long-term chemoradiation followed by consolidation FOLFIRINOX increases complete response rates and number of patients managed by WW.
Methods
Thiswas apragmatic randomized phase II trial conducted in 2 Cancer Centers in Brazil that included patients with T3+ or N+ rectal adenocarcioma. After completing long-course 54Gy chemoradiation with capecitabine patients were randomized 1:1 to observation or 4 cycles of mFOLFIRINOX (Oxaliplatin 85, irinotecan 135, 5-FU 2400). All patients were re-staged with dedicated pelvic MRI and sigmoidoscopy 12 weeks after the end of radiation. Patients with a clinical complete response were followed using a WW protocol. Primary enpoint was complete response: complete clinical response (cCR) or pathological response(pCR).
Results
Between Feb 2020 and April 2023, 46 patients were randomized to TNT and 42 to standard of care. Median age was 59 and 64% were male. Tumors were 68% stage 3, median distance from anal verge was 5cm, 43% had at-risk circumferential margin and 21% involved sphincter. The rates of cCR+pCR were 9/46 (19%) for TNT vs 5/42 (11%) for controls (OR 1.79, CI95% 0.54-6.3 p=0.16) and rates of WW were 5/46 (10.8%) and 2/45 (4%) (ns). Median follow-up was 16.9 months and recurrence rates were 8/46 (17%) and 11/42 (26%) for TNT and controls (ns).
Conclusions
TNT with consolidation FOLFIRINOX is feasible and has high response rates. Complete data from 96 patients will be presented at the meeting. This trial was supported by a grant from the Brazilian Ministry of Health (PROADI-SUS) - NUP 25000.164382/2020-81.
Clinical trial identification
NCT05081687.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Brazilian Ministry of Health - "PROADI-SUS".
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
580P - Prognosis in stage II colorectal cancer: The effect of the primary tumor location and biomarkers
Presenter: Vincent Liégeois
Session: Poster session 10
581P - The effect of exercise intervention on defecation related symptoms of colorectal cancer patients a randomized controlled trial
Presenter: Justin Jeon
Session: Poster session 10
582P - High accuracy of a blood-based multimodal ctDNA test to detect advanced neoplasms in a FIT-positive screening population
Presenter: Joana Vidal Barrull
Session: Poster session 10
583P - A rapid blood test for the earlier detection of colorectal cancer
Presenter: Jennifer Nobes
Session: Poster session 10
584P - Two-year update of the prospective evaluation of ColonAiQ (PreC) study
Presenter: Yanbing Ding
Session: Poster session 10
585P - Fragmentomics early detection assay leading to potential clinical benefits in colorectal cancer
Presenter: Yuepeng Cao
Session: Poster session 10
586P - Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Presenter: Daphne Day
Session: Poster session 10
588P - PLCRC-PROVENC3 study: Prognostic value of post-surgery liquid biopsy circulating tumor DNA in stage III colon cancer patients
Presenter: Carmen Rubio-Alarcón
Session: Poster session 10
589P - Impact of landmark point selection on molecular residual disease detection in stage I-IV resectable colorectal cancer
Presenter: Di Cao
Session: Poster session 10